1-3 of 3
Eric Charpentier
Close
Sort by
Journal Articles

A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma

Clinical Trials & Observations
Thomas Martin, Rachid Baz, Don M. Benson, Nikoletta Lendvai, Jeffrey Wolf, Pamela Munster, Alexander M. Lesokhin, Claudine Wack, Eric Charpentier, Frank Campana, Ravi Vij
Journal: Blood
Blood (2017) 129 (25): 3294–3303.
https://doi.org/10.1182/blood-2016-09-740787
Published: 2017
Journal Articles

A Dose Finding Phase II Trial of Isatuximab (SAR650984, Anti-CD38 mAb) As a Single Agent in Relapsed/Refractory Multiple Myeloma

Thomas Martin, MD, Joshua Richter, MD, Ravi Vij, MD, Craig Cole, MD, Djordje Atanackovic, MD, Jeffrey Zonder, MD, Jonathan L. Kaufman, MD, William Bensinger, MD, Meletios A. Dimopoulos, Jesús San Miguel, MDPhD, Todd Zimmerman, MD, Nikoletta Lendvai, MDPhD, Parameswaran Hari, MD MRCP, MS, Enrique M. Ocio, MD PhD, Cristina Gasparetto, MD, Shaji Kumar, MD, Karl Hsu, MD, Eric Charpentier, MSc, Stephen A. Strickland, MD, Joseph Mikhael, MD
Journal: Blood
Blood (2015) 126 (23): 509.
https://doi.org/10.1182/blood.V126.23.509.509
Published: 2015
Journal Articles

A Phase Ib Dose Escalation Trial of SAR650984 (Anti-CD-38 mAb) in Combination with Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma

Thomas G. Martin, MD, Rachid Baz, MD, Don M. Benson, MD PhD, Nikoletta Lendvai, MD PhD, Frank Campana, MD, Eric Charpentier, Ravi Vij, MBBS, MD
Journal: Blood
Blood (2014) 124 (21): 83.
https://doi.org/10.1182/blood.V124.21.83.83
Published: 2014